In the News

413 News Items found
MSK scientists Charles Rudin and John Poirier
In the Lab
An epigenetic mechanism may make small cell lung cancer vulnerable to a new kind of attack.
A tube of blood superimposed on a lung and a DNA helix
In the Clinic
The initial results of an ongoing study show that a liquid biopsy has advantages over a tissue biopsy for people with lung cancer.
MSK thoracic oncologist Kathryn Arbour, MD, seen smiling.
Learn how MSK doctors are treating lung cancer in clinical trials with daraxonrasib, which targets RAS mutations in tumors.
scientific image
In the Clinic
Overcoming resistance to drug treatment for lung cancer is a critical challenge.
Charles Rudin and David Jones, leaders of the Druckenmiller Center
In the Clinic
The new Fiona and Stanley Druckenmiller Center for Lung Cancer Research brings together MSK physicians and scientists in an intensive, multidisciplinary effort against the number-one cause of death from cancer in the nation.
Memorial Sloan Kettering neuro-oncologist Adrienne Boire
Roundup
Read about some of the most important clinical advances made at MSK in 2020.
Charles Rudin and Dana Pe'er
Stem-like cells that make up only a tiny fraction of the total cells in a lung tumor could be the key to stopping the disease’s deadly spread, say researchers at Memorial Sloan Kettering.
Three photos of Karen Milich: one with her grandson, one of her with her sons, and one of her alone
Feature
Read how a clinical trial is changing the outlook for some people with lung cancer.
Lung cancer has an uncanny ability to change its identity to resist drugs. Researchers are learning what drives these changes.
Alexander Drilon, MD
The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to selpercatinib (Retevmo™) for lung and thyroid cancers with RET (REarranged during Transfection) gene mutations or fusions.